Welcome to our dedicated page for Mynd Life Scienc news (Ticker: MYNDF), a resource for investors and traders seeking the latest updates and insights on Mynd Life Scienc stock.
MYND Life Sciences Inc. (MYNDF) is a clinical-stage biotechnology company advancing innovative diagnostic tools and therapies for depression treatment. This page serves as the definitive source for official news and press releases related to their biomarker development programs, neuropharmaceutical research, and corporate developments.
Investors and researchers will find timely updates on key initiatives including the MYND Anti-Inflammatory Peptide (MAP) diagnostic test, psilocybin-based therapeutic research, and strategic financial management activities. The curated news collection provides essential insights into clinical trial progress, intellectual property advancements, and partnership announcements.
All content undergoes rigorous verification to ensure accuracy and compliance with financial disclosure standards. Regular updates cover material developments across three core areas: diagnostic biomarker validation, drug candidate research, and balance sheet optimization strategies.
Bookmark this page for direct access to primary source information about MYNDF's progress in developing precision medicine solutions for neuropsychiatric disorders. Check back regularly for verified updates that matter to stakeholders in the life sciences investment community.
Mynd Life Sciences Inc. (CNSX: MYND) has been granted a management cease trade order (MCTO) on March 3, 2025, affecting certain company insiders. The order comes after the company's inability to file its annual consolidated financial statements for the year ended October 31, 2024, before the February 28, 2025 deadline.
The delay is attributed to the company's external auditors requiring additional time to complete their work due to significant restructuring of the Company's debt and equity. The company expects to file the required 2024 Annual Filings by April 29, 2025.
The MCTO restricts trading in company securities by the CEO and CFO but does not affect other shareholders' ability to trade. The company has been placed on the British Columbia Securities Commission's defaulting issuers list due to non-compliance with continuous disclosure obligations.
MYND Life Sciences Inc. (CSE: MYND) has received a management cease trade order (MCTO) on March 3, 2025, affecting trading by company insiders. The order comes after external auditors indicated they couldn't complete the annual consolidated financial statements for the year ended October 31, 2024, by the February 28, 2025 deadline.
The delay is attributed to significant restructuring of the Company's debt and equity. MYND expects to file the required 2024 Annual Filings, including financial statements, MD&A, CEO/CFO certifications, and Annual Information Form by April 29, 2025. The company has been placed on the defaulting issuers list of the British Columbia Securities Commission.
The MCTO specifically restricts trading by the CEO and CFO but does not affect other shareholders' ability to trade their securities. Management continues to work on completing the required filings.
Mynd Life Sciences (CNSX: MYND) has announced a delay in filing its annual consolidated financial statements for the year ended October 31, 2024. The company's external auditors informed that they cannot complete their work before the February 28, 2025 deadline due to significant restructuring of the company's debt and equity.
As a result, Mynd will be unable to file the 2024 Annual Filings, including Management Discussion & Analysis, CEO and CFO certifications, and Annual Information Form by the required deadline. The company plans to complete and file these documents by April 29, 2025.
Following this delay, Mynd will be placed on the British Columbia Securities Commission's defaulting issuers list and has been granted a management cease trade order (MCTO) against certain company insiders. The MCTO will remain in effect until the audited statements are filed and must issue bi-weekly default status reports through press releases.
MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF), a clinical-stage life sciences company focused on depression treatments, has announced a shares for debt transaction to settle outstanding debt of $2,273,062.30. The company will issue 22,730,623 common shares at a deemed price of $0.10 per share to creditors, including certain related parties.
The shares will be subject to a four-month plus one day hold period as per Canadian Securities Exchange policies. The transaction qualifies as a 'related party transaction' under MI 61-101 but is exempt from valuation and minority shareholder approval requirements as the shares are not listed on specified markets and the fair market value doesn't exceed 25% of the company's market capitalization.
MYND Life Sciences (MYNDF) has announced the Board's approval to issue 4,000,001 common shares at $0.71 per share, settling a previously announced $3.5 Million (CDN) debenture from January 10, 2025. The total value of the share issuance amounts to $2,840,000.71.
The company, focused on developing drug therapies and diagnostics for depression treatment and monitoring, considers this a significant milestone. According to CFO Lih Tam, this development enables MYND to engage with the investment community while advancing their mission to address major depressive disorder. The debenture settlement details will be reflected in upcoming financial statements.
MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) has announced two strategic moves to strengthen its position. The company has converted $800,619.65 (CDN) in loan and officer deferred salary debt into company shares, demonstrating leadership's commitment to its vision of commercializing a diagnostic biomarker test for depression. Additionally, Lana Hoogenboom, a pharmaceutical industry veteran with 12 years of experience at Otsuka Canada, has been appointed to the Board of Directors to advance commercialization strategies and partnership initiatives.
MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) announced a proposed issuance of 4 million shares at $0.71 per share to eliminate $3.5 million in debt, including an outstanding debenture. The debenture was originally issued to support the company's development of a diagnostic biomarker for major depressive disorder (MDD), Phase 2B Alzheimer's trial, and IL-33 biomarker for cancer monitoring. The company is now focusing solely on developing the MDD diagnostic biomarker. The new shares will be subject to a four-month hold period from issuance, pending regulatory approval.
